drugset

drugset / Trial / NCT00167609

Efficacy and Safety of DHEA for Myotonic Dystrophy

NCT00167609 ↗

Phase 2/3 Completed 75 enrolled University of Versailles Assistance Publique - Hôpitaux de Paris · collab Association Française contre les Myopathies (AFM), Paris · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

To test the efficacy and safety of two doses of dehydroepiandrosterone (DHEA) in adults with myotonic dystrophy

Timeline

Start: 2004-11
Primary completion: —
Completion: 2006-12

Publications

Results Penisson-Besnier I, Devillers M, Porcher R, Orlikowski D, Doppler V, Desnuelle C, Ferrer X, Bes MC, Bouhour F, Tranchant C, Lagrange E, Vershueren A, Uzenot D, Cintas P, Sole G, Hogrel JY, Laforet P, Vial C, Vila AL, Sacconi S, Pouget J, Eymard B, Chevret S, Annane D. Dehydroepiandrosterone for myotonic dystrophy type 1. Neurology. 2008 Aug 5;71(6):407-12. doi: 10.1212/01.wnl.0000324257.35759.40.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dehydroepiandrosterone	Other / unclassified	100 mg	Oral
Subject	Dehydroepiandrosterone	Other / unclassified	400 mg	Oral

Indications